In ER+/HER2− advanced breast cancer after a CDK4/6 inhibitor, giredestrant plus everolimus improved PFS vs standard endocrine therapy plus everolimus: median 10.0 vs 5.5 months in ESR1-mutated (HR 0.38) and 8.8 vs 5.5 overall (HR 0.56); adverse events similar.
RCTn = 373
Mayer et al. Giredestrant plus Everolimus in Advanced Breast Cancer